Bladder cancer is the fourth most common cancer in men and the tenth in women Additionally.

The company is focused investors are Karolinska Development AB (Ed. Finnish Industry Investment Ltd., and Etra Invest Oy.. Bladder cancer is the fourth most common cancer in men and the tenth in women Additionally, the high recurrence rate, with approximately 70 percent in patients with non – invasive form of cancer, where the malignancy is surface surface layers of the bladder not. – invasive bladder cancer by urologists using local surgery and intravesical drug therapy administered directly into the bladder treated Existing drug therapies often have undesirable side effects and limited efficacy. BioCis Pharmaceuticals Ltd.

.. The open-label, is a dose-escalation study will assess the safety, tolerability and pharmacokinetics of the administered locally product in 22 patients with primary or recurrent non – muscle invasive bladder cancer, and it is anticipated well tolerated. We are pleased the clinical trial the clinical trial with ProtoCure instillation solution, says Lasse Leino, CEO of BioCis pharmaceutical. It is our first oncology products this important milestone this important milestone and follows the initiation of two Phase 2a studies with our lead anti-inflammatory product in patients with inflammatory diseases of the skin, recently announced.While the exact cause is unknown, thyroid disease tended, in family and radiation dose is thought that to run a risk factor thyroid cancer. The increased availability of high quality, non-invasive screening such as ultrasonic most likely more cases that have at any age, tells Seybt identify.

Many of our older patients have other problems, like cardiac insufficiency , hypertension and restrictive lung disease, we are very aggressively so medical certificate from and optimization of control over their the other problems, says Seybt.

But they trial by 428 patients with thyroidectomy MCGHealth Medical Center and Charlie Norwood Veterans Affairs Medical Center from November 2003 and December 2007 , including 44 patients above 65 years and 86 aged 21-35 showed some difference between the two groups.